Login to Your Account



Regeneron, Sanofi report sarilumab beats Humira in monotherapy trial for RA

By Michael Fitzhugh
Staff Writer

Friday, March 11, 2016

With sarilumab cruising toward a potential FDA approval this fall or earlier, drug developers Sanofi SA and Regeneron Pharmaceuticals Inc. reported that, at week 24, the interleukin-6 receptor antibody beat Humira monotherapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription